Express Pharma
Home  »  Archive  »  DRL launches Duloxetine

DRL launches Duloxetine

0 30
Read Article

Dr Reddy’s Laboratories (DRL) has launched Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg, a therapeutic equivalent generic version of Cymbalta (Duloxetine delayed-release capsules) in the US market. DRL’s ANDA is approved by the United States Food & Drug Administration (USFDA).

The Cymbalta brand and generic had US sales of approximately $5.04 billion MAT for the most recent twelve months ending in April 2014 according to IMS Health.

Dr Reddy’s Duloxetine delayed-release capsules USP 20 mg, 30 mg and 60 mg are available in several bottle counts.

EP News BureauMumbai

Leave A Reply

Your email address will not be published.